Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Transplant-eligible Patients”

121 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 121 results

Testing effectiveness (Phase 2)Study completedNCT02771197
What this trial is testing

Lymphodepletion and Anti-PD-1 Blockade to Reduce Relapse in AML Patient Not Eligible for Transplant

Who this might be right for
Acute Myeloid Leukemia
Northside Hospital, Inc. 20
Testing effectiveness (Phase 2)Study completedNCT00799513
What this trial is testing

Trial on Lenalidomide Given as Maintenance Therapy for Relapsed Diffuse Large B Cell Lymphoma

Who this might be right for
Diffuse Large B-cell Lymphoma
IRCCS San Raffaele 48
Testing effectiveness (Phase 2)WithdrawnNCT01170052
What this trial is testing

Bendamustine and Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Non-Hodgkin's Lymphoma (NHL)

Who this might be right for
Mantle Cell Lymphoma
Charite University, Berlin, Germany 20
Large-scale testing (Phase 3)Looking for participantsNCT07297329
What this trial is testing

Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

Who this might be right for
Multiple Myeloma (MM)
Sinocelltech Ltd. 292
Large-scale testing (Phase 3)Active Not RecruitingNCT04934475
What this trial is testing

MInimal Residual Disease Adapted Strategy

Who this might be right for
Multiple Myeloma
Intergroupe Francophone du Myelome 791
Not applicableStudy completedNCT03106324
What this trial is testing

A Safety Study of Lenalidomide in Previously Untreated Adult Multiple Myeloma Patients Who Are Not Eligible for Transplant

Who this might be right for
Multiple Myeloma
Celgene 911
Very early researchUnknownNCT05840107
What this trial is testing

Study of FasT CAR-T GC012F Injection NDMM Patients

Who this might be right for
Multiple Myeloma
Shanghai Changzheng Hospital 18
Large-scale testing (Phase 3)Ended earlyNCT02145598
What this trial is testing

Treatment Optimization in Patients With Untreated Multiple Myeloma

Who this might be right for
Multiple Myeloma
Dr. med. Lars-Olof Muegge 85
Testing effectiveness (Phase 2)UnknownNCT04935580
What this trial is testing

Study of FasT CAR-T GC012F Injection in High Risk TE NDMM Patients

Who this might be right for
Multiple Myeloma
Shanghai Changzheng Hospital 20
Large-scale testing (Phase 3)Study completedNCT03595800
What this trial is testing

Extension of a Study of Allogeneic Hematopoietic Stem Cell Transplantation From One Haplotype Mismatch Related Donor or From an Unrelated Donor to Younger Patients Eligible for Reduced-intensity Conditioning Regimen

Who this might be right for
Acute LeukemiaNon Hodgkin LymphomaMultiple Myeloma
Institut Paoli-Calmettes 9
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07070934
What this trial is testing

CAR-T vs. Auto-SCT: Which Works Better for New Myeloma Patients?

Who this might be right for
Multiple MyelomaNewly Diagnosed
Xuzhou Medical University 60
Testing effectiveness (Phase 2)UnknownNCT02955628
What this trial is testing

RICE-ibrutinib in Relapsed DLBCL

Who this might be right for
Diffuse Large B Cell LymphomaDiffuse Large B-Cell Lymphoma Recurrent
Singapore General Hospital 34
Large-scale testing (Phase 3)Active Not RecruitingNCT03319667
What this trial is testing

Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

Who this might be right for
Plasma Cell Myeloma
Sanofi 475
Not applicableLooking for participantsNCT06675617
What this trial is testing

EXtensive mulTilayer stEnt treatmeNt in Aortic disSectiOn

Who this might be right for
Type B Aortic Dissection
Intressa Vascular SA 72
Not applicableWithdrawnNCT03172559
What this trial is testing

Radiotherapy Versus no Intervention in Adult Patients With Hepatocellular Carcinoma Not Eligible for Transarterial Chemoembolization or Ablation Prior to Liver Transplant (RADBRI)

Who this might be right for
Hepatocellular Carcinoma
University Health Network, Toronto
Not applicableUnknownNCT05218603
What this trial is testing

Evaluation of Maintenance With Bortezomib Plus Daratumumab (V-Dara) After Induction With Bortezomib, Melphalan, Prednisone Plus Daratumumab (VMP-Dara) in Newly Diagnosed Multiple Myeloma (MM) Patients Non-eligible for autoSCT

Who this might be right for
Multiple MyelomaNon-eligible for Autologous Stem Cell Transplantation (ASCT)
PETHEMA Foundation 100
Post-approval studies (Phase 4)Study completedNCT03677596
What this trial is testing

Two Inotuzumab Ozogamicin Doses in Relapsed/ Refractory Acute Lymphoblastic Leukemia Transplant Eligible Patients

Who this might be right for
LeukemiaPrecursor b-Cell Lymphoblastic Leukemia-LymphomaACUTE LYMPHOBLASTIC LEUKEMIA
Pfizer 102
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07828522
What this trial is testing

F182112 in Combination With Isatuximab and Lenalidomide for the Treatment of Patients With Newly Diagnosed Multiple Myeloma

Who this might be right for
Multiple Myeloma (MM)Transplant-eligible Patients
Institute of Hematology & Blood Diseases Hospital, China 10
Testing effectiveness (Phase 2)Temporarily pausedNCT05199311
What this trial is testing

Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple Myeloma

Who this might be right for
Multiple Myeloma
Hackensack Meridian Health 66
Testing effectiveness (Phase 2)Looking for participantsNCT06505369
What this trial is testing

Bispecific T-cell Redirectors as Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients

Who this might be right for
Multiple Myeloma
North Estonia Medical Centre 50
Next Page